Essiac

Domain XII · Complementary, energy & biofield · Rene Caisse · 1922 · Canada

What it is

Ingredients (names only). Essiac: burdock root, Indian rhubarb root, sheep sorrel, slippery elm inner bark. Flor Essence adds watercress, blessed thistle, red clover and kelp. Brand names include Essiac, Vitaltea and Flor-Essence; CAM-Cancer reports more than 40 formulas sold worldwide.

Format

• Consent and pressure. The remedy was given free during the clinic years, which framed it as charity rather than commerce. No record describes information about lack of evidence being given; the formula itself was kept secret, so patients could not know what they were taking.
• Compassionate-access and trial era (late 1970s to 1980s). Doctors requested supply for individual patients. The investigational trial was not randomised, had no controls, and treatment was usually given at patients' own request; it was judged inconclusive and cancelled. A government review of…

Who practises it, and how they are trained or regulated

• In 1977 Caisse passed a four-herb recipe to a Canadian company (spelled Respirin by Clow, Resperin in NCI references), reportedly for a small sum; she died in December 1978. That company dissolved in 1995 and a new company was formed to market the mixture; CAM-Cancer names David Dobbie as buying the formula and trademark in 1995. Essiac is now a registered trademark held by Essiac Canada International.
• To referrers and regulators: from 1978 the company obtained Canadian permission for clinical study; this was withdrawn in 1982 for failure to meet commitments on manufacturing control, characterising active substances and trial design; a US New Drug Application was unsuccessful. Physicians could request it for patients under Canada's Emergency Drug Release (Special Access) Programme; promotion as a cancer treatment…
• In the 1980s, Essiac-like products moved to being marketed as "health tonics" rather than drugs, which took them outside drug regulation. Today Essiac is not licensed as a medicine and is usually sold as a nutritional supplement.

Evidence status, as the guide reports it

• Consent and pressure. The remedy was given free during the clinic years, which framed it as charity rather than commerce. No record describes information about lack of evidence being given; the formula itself was kept secret, so patients could not know what they were taking.

Questions to explore with your client

• What drew you to it, and what are you hoping it will change?
• Does it involve any substance, plant preparation, remedy or supplement? Has your doctor or prescriber been told, especially about any medication you take?
• Does it involve fasting, a special diet or 'detox'? Have you discussed this with your doctor?
• Is it a group, retreat or community? How do they respond if someone wants to leave or raises a concern?
• Does it use a device, heat, cold, water or a physical procedure? Has a medical professional checked that it is safe for you?
• Who runs it, and what training or registration do they hold?
• What actually happens in a session or meeting, and how often?
• What does it cost, and is there pressure to commit to more?
• How do you feel afterwards, in the hours and days that follow?
• Does it fit with, or clash with, the work we do here?

What practitioners of it watch for

• shame preventing disclosure; continued buying despite harm. It is working when the client sets limits or seeks redress.
• missed paediatric oncology appointments; secrecy; group or seller influence on parents. It is working when the child's care team is engaged.
• coercion in either direction; an adult patient's autonomy being overridden; caregivers' unspoken grief. It is working when the family can discuss the plan without rupture.
• collusion with unrealistic expectations versus crushing hope; caregiver burnout. It is working when symptom needs are addressed and conversations about goals become possible.
• clients asking for the therapist's endorsement; the therapist feeling pulled to rescue or to argue. It is working when the client brings product questions to their medical team.

Problems the guide addresses

• Asking about remedy use routinely and without judgement
• Exploring meaning, hopes and the client's explanatory model
• Autonomy-respecting decision support
• Coordination with the oncologist, doctor and pharmacist
• Responding when a client delays or declines conventional treatment
• Supporting hope and palliative referral in advanced illness
• Grief, regret and guilt after choosing an alternative
• Family conflict
• Financial harm and exploitation
• Safeguarding children and adults at risk

When to involve someone else

• New or worsening physical symptoms, or advice to stop or change prescribed medication: involve the client's doctor or prescriber.
• Signs of coercion, isolation from family and friends, escalating costs or secrecy: discuss openly and consider safeguarding.
• A crisis or thoughts of suicide: follow your crisis protocol. In the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.

Drawn automatically from the guide's own sections. Stay curious: neither endorse nor dismiss what the client values, and check anything that matters against the full guide and its sources. Not medical advice.